A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs Atogepant (Primary) ; Antimigraines
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Allergan
- 21 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2018 Status changed from not yet recruiting to recruiting.
- 12 Oct 2018 New trial record